{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:37:29Z","timestamp":1779100649365,"version":"3.51.4"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lfs.2018.09.058","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T02:19:37Z","timestamp":1538533177000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Cannabinoids in depressive disorders"],"prefix":"10.1016","volume":"213","author":[{"given":"Ewa","family":"Poleszak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Wo\u015bko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"S\u0142awi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-2904","authenticated-orcid":false,"given":"Aleksandra","family":"Szopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5732-8950","authenticated-orcid":false,"given":"Anna","family":"Serefko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2018.09.058_bb0005","first-page":"217","article-title":"Activation of endocannabinoid transmission induces antidepressant-like effects in rats","volume":"59","author":"Adamczyk","year":"2008","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.euroneuro.2010.06.007","article-title":"Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype","volume":"21","author":"Aso","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0015","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1471-4159.2007.05149.x","article-title":"BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice","volume":"105","author":"Aso","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2018.09.058_bb0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.tpj.6500301","article-title":"Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)","volume":"5","author":"Barrero","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.lfs.2018.09.058_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fnbeh.2012.00009","article-title":"The endocannabinoid system: an overview","volume":"6","author":"Battista","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.nbd.2010.03.020","article-title":"Depression-like phenotype following chronic CB1 receptor antagonism","volume":"39","author":"Beyer","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.lfs.2018.09.058_bb0035","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2006.12.001","article-title":"Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress","volume":"62","author":"Bortolato","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drugalcdep.2014.08.005","article-title":"Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications","volume":"144","author":"Castaneto","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.lfs.2018.09.058_bb0045","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0006-2952(93)90486-G","article-title":"Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist","volume":"46","author":"Deutsch","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0050","first-page":"3216","article-title":"Why do cannabinoid receptors have more than one endogenous ligand?","volume":"367","author":"Di Marzo","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0055","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/npp.2012.36","article-title":"Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice","volume":"37","author":"Dubreucq","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.phrs.2009.12.013","article-title":"A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy","volume":"61","author":"Eisenstein","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0065","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2018.09.058_bb0070","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.prostaglandins.2013.02.002","article-title":"Endogenous cannabinoids revisited: a biochemistry perspective","volume":"102\u2013103","author":"Fonseca","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"10.1016\/j.lfs.2018.09.058_bb0075","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.lfs.2018.09.058_bb0080","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors","volume":"160","author":"Garcia-Gutierrez","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0085","doi-asserted-by":"crossref","first-page":"18620","DOI":"10.1073\/pnas.0509591102","article-title":"Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis","volume":"102","author":"Gobbi","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lfs.2018.09.058_bb0090","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2006.10.028","article-title":"Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness","volume":"554","author":"Gobshtis","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.mp.4001032","article-title":"Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH\/NE states","volume":"7","author":"Gold","year":"2002","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0100","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1523\/JNEUROSCI.2737-14.2015","article-title":"Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety","volume":"35","author":"Gray","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.psyneuen.2016.01.004","article-title":"Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function","volume":"6","author":"Gray","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","article-title":"Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents","volume":"57","author":"Griebel","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0115","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1460-9568.2004.03293.x","article-title":"Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice","volume":"19","author":"Haller","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0125","series-title":"Nutraceuticals Efficacy, Safety and Toxicity","first-page":"735","article-title":"Cannabis sativa and hemp","author":"Hartsel","year":"2016"},{"key":"10.1016\/j.lfs.2018.09.058_bb0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1471-4159.2007.04688.x","article-title":"Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity","volume":"103","author":"Hill","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2018.09.058_bb0135","series-title":"Phamacologically Distinct Antidepressants Differentially Regulate the Endocannabinoid System. 15th Annual Symposium on the Cannabinoids, (Abstract), Clearwater Beach, Florida, USA June","first-page":"24","author":"Hill","year":"2005"},{"key":"10.1016\/j.lfs.2018.09.058_bb0140","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/j.1471-4159.2008.05567.x","article-title":"Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment","volume":"106","author":"Hill","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.lfs.2018.09.058_bb0145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.euroneuro.2005.03.003","article-title":"Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test","volume":"15","author":"Hill","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0150","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1038\/sj.npp.1301092","article-title":"Involvement of endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypotalamic-pituitary-adrenal axis","volume":"31","author":"Hill","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2007-993211","article-title":"Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report","volume":"41","author":"Hill","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.lfs.2018.09.058_bb0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pain.2009.02.018","article-title":"Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833","volume":"143","author":"Hu","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.lfs.2018.09.058_bb0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.mp.4001376","article-title":"Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims","volume":"9","author":"Hungund","year":"2004","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0175","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.26142","article-title":"The therapeutic potential of cannabinoids for movement disorders","volume":"30","author":"Kluger","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.lfs.2018.09.058_bb0180","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s00702-007-0660-5","article-title":"Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression","volume":"114","author":"Koethe","year":"2007","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.lfs.2018.09.058_bb0185","first-page":"99","article-title":"The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans","volume":"61","author":"Komorowski","year":"2007","journal-title":"Postepy Hig. Med. Dosw. (Online)"},{"key":"10.1016\/j.lfs.2018.09.058_bb0190","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/978-3-540-74805-2_14","article-title":"Presynaptic modulation by endocannabinoids","author":"Lovinger","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1300\/J175v01n01_05","article-title":"Therapeutic use of Cannabis sativa L. in Arabic medicine","volume":"1","author":"Lozano","year":"2001","journal-title":"Journal of Cannabis Therapeutics"},{"key":"10.1016\/j.lfs.2018.09.058_bb0200","series-title":"Paper Presented at the 37th Meeting of the Expert Committee on Drug Dependence","article-title":"Update of cannabis and its medical use","author":"Madras","year":"2015"},{"key":"10.1016\/j.lfs.2018.09.058_bb0205","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0006-8993(99)01756-4","article-title":"Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats","volume":"839","author":"Manzanares","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00213-001-0946-5","article-title":"Involvement of CB1 cannabinoid receptors in emotional behaviour","volume":"159","author":"Martin","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0215","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2018.09.058_bb0220","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","article-title":"Endocannabinoid system and mood disorders: priming a target for new therapies","volume":"138","author":"Micale","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.lfs.2018.09.058_bb0225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejphar.2018.07.039","article-title":"Endocannabinoid system, stress and HPA axis","volume":"834","author":"Micale","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0230","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00441-013-1692-9","article-title":"Leading compounds for the validation of animal models of psychopathology","volume":"354","author":"Micale","year":"2013","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0235","series-title":"Cannabinoid Modulation of Emotion, Memory, and Motivation","first-page":"97","article-title":"Role of the endocannabinoid system in depression: from preclinical to clinical evidence. In Campolongo, Patrizia., Fattore, Liana","author":"Micale","year":"2015"},{"key":"10.1016\/j.lfs.2018.09.058_bb0240","series-title":"Bidirectional Alterations in Serum Endocannabinoids in Minor and Major Depression. Program No 107.3 2005 (Abstract) Viewer\/Itinerary Planner","author":"Miller","year":"2005"},{"key":"10.1016\/j.lfs.2018.09.058_bb0245","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.phrs.2010.01.002","article-title":"Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression","volume":"61","author":"Monteleone","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0250","first-page":"21","article-title":"Use of cannabis and its derivatives. Part II. Their use in medicine vs. health consequences","volume":"9","author":"Motyka","year":"2014","journal-title":"Probl. Hig. Epidemiol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2018.09.058_bb0260","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/bph.12411","article-title":"Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS","volume":"171","author":"Murataeva","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0265","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00213-006-0689-4","article-title":"Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality","volume":"192","author":"Naidu","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0270","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2014.04.014","article-title":"The dual blocker of FAAH\/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis","volume":"87","author":"Navarria","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0275","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.neuropharm.2005.04.014","article-title":"Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain","volume":"49","author":"Oliva","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0001640","article-title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects","volume":"3","author":"Onaivi","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.09.058_bb0285","first-page":"291","article-title":"Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression","volume":"123","author":"Onaivi","year":"2006","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.lfs.2018.09.058_bb0290","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/1440-1681.12518","article-title":"Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice","volume":"43","author":"Ostadhadi","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0295","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tins.2008.06.006","article-title":"The HPA axis in major depression: classical theories and new developments","volume":"31","author":"Pariante","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0300","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-3-540-88955-7_14","article-title":"Role of endocannabinoid signaling in anxiety and depression","volume":"1","author":"Patel","year":"2009","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0305","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1210\/en.2004-0638","article-title":"Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis","volume":"145","author":"Patel","year":"2004","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"10.1016\/j.lfs.2018.09.058_bb0310","first-page":"S163","article-title":"Cannabinoid pharmacology: the first 66\u202fyears","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0006-8993(02)03055-X","article-title":"Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study","volume":"948","author":"Pistis","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0320","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.301.3.1020","article-title":"Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor","volume":"301","author":"Porter","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2018.09.058_bb0325","series-title":"Program No 653.16 2005 (Abstract) Viewer\/Itinerary Planner","article-title":"Effect of AVE1625, a novel cannabinoid CB1 receptor antagonist, in models of aggression and depression","author":"Pratt","year":"2005"},{"key":"10.1016\/j.lfs.2018.09.058_bb0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1192\/bjp.178.2.107","article-title":"Therapeutic aspects of cannabis and cannabinoids","volume":"178","author":"Robson","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0335","series-title":"Medicinal Plants of the World. Chemical Constituents, Traditional and Modern Medicinal Uses","first-page":"29","author":"Ross","year":"2005"},{"key":"10.1016\/j.lfs.2018.09.058_bb0340","first-page":"165","article-title":"Antidepressant\u2014like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors","volume":"61","author":"Rutkowska","year":"2004","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.lfs.2018.09.058_bb0345","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","article-title":"Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice","volume":"14","author":"Shearman","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0350","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.neuint.2003.08.009","article-title":"Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex\u2014involvement of Na(+)\/K(+)-ATPase","volume":"44","author":"Steffens","year":"2004","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.lfs.2018.09.058_bb0355","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.psyneuen.2007.09.008","article-title":"Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0360","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.psyneuen.2008.06.004","article-title":"Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses","volume":"33","author":"Steiner","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0365","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.tpj.6500466","article-title":"Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice","volume":"8","author":"Steiner","year":"2008","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.lfs.2018.09.058_bb0370","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/42015","article-title":"A second endogenous cannabinoid that modulates long-term potentiation","volume":"388","author":"Stella","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.lfs.2018.09.058_bb0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.pbb.2008.05.010","article-title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review","volume":"90","author":"Svizenska","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2018.09.058_bb0380","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnbeh.2011.00049","article-title":"The dopamine and cannabinoid interaction in the modulation of emotions and cognition: assessing the role of cannabinoid CB1 receptor in neurons expressing dopamine D1 receptors","volume":"5","author":"Terzian","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0385","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/sj.bjp.0705100","article-title":"The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions","volume":"138","author":"Tzavara","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb0390","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bbr.2011.04.031","article-title":"Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice","volume":"223","author":"Umathe","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0395","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.neuropharm.2004.01.003","article-title":"Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors","volume":"46","author":"Uriguen","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.lfs.2018.09.058_bb0400","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.2337\/dc08-s258","article-title":"Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the rimonabant in obesity (RIO) program","author":"Van Gaal","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lfs.2018.09.058_bb0405","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.biopsych.2004.11.033","article-title":"Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims","volume":"57","author":"Vinod","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.lfs.2018.09.058_bb0410","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.tips.2006.08.006","article-title":"Role of the endocannabinoid system in depression and suicide","volume":"27","author":"Vinod","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.lfs.2018.09.058_bb0415","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jpsychires.2009.11.013","article-title":"Selective alterations of the CB1 receptors and the fatty acid amide hydrolase in the ventral striatum of alcoholics and suicides","volume":"44","author":"Vinod","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.lfs.2018.09.058_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036743","article-title":"Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats","volume":"7","author":"Vinod","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2018.09.058_bb0425","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.pbb.2005.01.029","article-title":"Endocannabinoid system and stress and anxiety responses","volume":"81","author":"Viveros","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.lfs.2018.09.058_bb0430","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/0269881111409606","article-title":"Acute restraint stress enhances hippocampal endocannabinoid function via glucocorticoid receptor activation","volume":"26","author":"Wang","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb1000","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/er.2005-0009","article-title":"The emerging role of the endocannabinoid system in endocrine regulation and energy balance","volume":"27","author":"Pagotto","year":"2006","journal-title":"Endocr Rev."},{"key":"10.1016\/j.lfs.2018.09.058_bb2000","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.lfs.2018.09.058_bb3000","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0705607","article-title":"Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors","volume":"141","author":"Leggett","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.lfs.2018.09.058_bb4000","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2018.08.012","article-title":"Selective up-regulation of cannabinoid CB1 receptor coupling to Go-proteins in suicide victims with mood disorders","author":"Mato","year":"2018","journal-title":"Biochem. Pharmacol."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518306040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320518306040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:15:18Z","timestamp":1758399318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320518306040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":89,"alternative-id":["S0024320518306040"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2018.09.058","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabinoids in depressive disorders","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2018.09.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}